- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- ALEMBIC PHARMA
ALEMBIC PHARMA Share Price 
(APLL)
Here is the latest stock price and chart of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Sep 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)638.65 | Open (Rs) 638.10 | High (Rs) 640.00 | Low (Rs) 630.80 |
| % Change1.04 | Volume 1,971 | Value (Rs) 1,255,046 | 52-Week H/L 662.00 / 412.40 |
| Live NSE Quotes | Sep 19, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)637.70 | Open (Rs) 628.15 | High (Rs) 640.00 | Low (Rs) 628.15 |
| % Change1.02 | Volume 31,127 | Value (Rs) 19,785,805 | 52-Week H/L 664.00 / 414.40 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 23.75 | P/E Ratio (x) 26.89 | Market Cap (Rs m) 120,398.30 | P/BV (x) 5.42 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
ALEMBIC PHARMA Share Price Today:
ALEMBIC PHARMA last traded price was up 1.0% to Rs 638.7 on the BSE. On the NSE, ALEMBIC PHARMA last traded price was up 1.0% to Rs 637.7. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.6%. And the benchmark S&P BSE SENSEX was at 37,121.2 (down 0.5%).
Over the last 30 days, the ALEMBIC PHARMA share price is up 8.5%. And over the last one year, ALEMBIC PHARMA share price is up 31.9%.
|
| |
Today's Market
Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)
After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.
Related Views On News
ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)
Sep 6, 2018The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?
Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)
Sep 12, 2018Richa has discovered the single most profitable opportunity in the market - read on to discover more...
The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)
Sep 7, 2018The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.
Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)
Sep 6, 2018Oil prices are rising and could go even more higher amid rising tensions in Middle East.
Should You Be Worried About the Rising Dollar?(Chart Of The Day)
Sep 7, 2018While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.
MoreTRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA 5-YR ANALYSIS
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.